Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial
Open Access
- 20 December 2021
- journal article
- research article
- Published by Elsevier in eClinicalMedicine
- Vol. 43, 101242
Abstract
No abstract availableKeywords
All Related Versions
This publication has 32 references indexed in Scilit:
- Cochrane Handbook for Systematic Reviews of Interventions2019
- Methods to adjust for multiple comparisons in the analysis and sample size calculation of randomised controlled trials with multiple primary outcomesBMC Medical Research Methodology, 2019
- A Tutorial on Multilevel Survival Analysis: Methods, Models and ApplicationsInternational Statistical Review, 2017
- Ranking treatments in frequentist network meta-analysis works without resampling methodsBMC Medical Research Methodology, 2015
- Tenofovir Selectively Regulates Production of Inflammatory Cytokines and Shifts the IL-12/IL-10 Balance in Human Primary CellsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Explanatory and Pragmatic Attitudes in Therapeutical TrialsJournal of Clinical Epidemiology, 2009
- The intention-to-treat approach in randomized controlled trials: Are authors saying what they do and doing what they say?Clinical Trials, 2007
- Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase InhibitorsArteriosclerosis, Thrombosis, and Vascular Biology, 2001
- Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T cell activation.Journal of the American Society of Nephrology, 1996
- The Quality in Australian Health Care StudyMedical Journal of Australia, 1995